EpiMonitor

Next-Gen Epilepsy Monitoring

Available in the US, UK, EU, AU, NZ and CA

Embrace2

Embrace2

Peace of Mind

No longer available for purchase

Empatica Logo
  • Solutions

    Empatica Health Monitoring Platform

    Empatica Health Monitoring Platform

    One platform, multiple applications

    Components

    EmbracePlus wearable
    EmbraceMini wearable
    New
    Care software suite
    eCOA
    Digital biomarkers
    Cloud API for Clinical Trials

    Use Cases

    Clinical Trials
    Designed for the patient, enhanced for the scientist
    Actigraphy
    The new standard to measure sleep and physical activity
    Contract Research Organizations
    Enhanced value and effortless integrations for CROs
    Parkinson's Monitoring
    New
    Improve patient outcomes with validated PKG measures
    Parkinson’s & Movement Disorders
    Digital endpoints & wearable monitoring for Parkinson’s and Movement Disorder Trials
    Academic Research
    Unlock the future of real-world research
    Go to store
  • Scientific Evidence

    Publications
    Scientific publications using our technology
    Case Studies
    Client success stories
  • Resources

    Compliance
    Global regulatory requirements
    Blog
    Thoughts and news
    Digital resources library
    Online and downloadable resources
    Support center
    Get support with our products
  • Company

    About us
    People with purpose
    Careers
    Join the mission
    Contact us
    Talk to our team
Contact Us
Empatica Logo
Empatica Health Monitoring Platform

Empatica Health Monitoring Platform

One platform, multiple applications

Components

EmbracePlus wearable
EmbraceMini wearable
New
Care software suite
eCOA
Digital biomarkers
Cloud API for Clinical Trials

Use Cases

Clinical Trials
Designed for the patient, enhanced for the scientist
Actigraphy
The new standard to measure sleep and physical activity
Contract Research Organizations
Enhanced value and effortless integrations for CROs
Parkinson's Monitoring
New
Improve patient outcomes with validated PKG measures
Parkinson’s & Movement Disorders
Digital endpoints & wearable monitoring for Parkinson’s and Movement Disorder Trials
Academic Research
Unlock the future of real-world research
Go to store
Publications
Scientific publications using our technology
Case Studies
Client success stories
Compliance
Global regulatory requirements
Blog
Thoughts and news
Digital resources library
Online and downloadable resources
Support center
Get support with our products
About us
People with purpose
Careers
Join the mission
Contact us
Talk to our team
EpiMonitor

Next-Gen Epilepsy Monitoring

Available in the US, UK, EU, AU, NZ and CA

Embrace2
Embrace2

Peace of Mind

No longer available for purchase

Contact Us
NewsProduct

Update: Embrace is Now an FDA-cleared Medical Device!

Empatica

Empatica

Feb 5, 2018• 3 min read

LinkedinFacebookX

We’re beyond excited to announce that the Embrace Watch has been cleared by the U.S. Food and Drug Administration as a medical device! This marks an invaluable milestone in our mission towards improving lives for millions of people in the epilepsy community.

We feel incredibly proud to have met FDA’s requirements, which are considered to be the most rigorous among all healthcare regulatory bodies around the world.

We started with the filing work in mid-2016, and our final package reached 1,500 pages, where we’ve presented the scientific evidence and technical details around the Embrace system.

Seizure monitoring research had started in 2007 at the MIT Media Lab with Dr. Rosalind Picard — Director of the Affective Computing Group and Chief Scientist at Empatica, who began working on a wearable that measured electrodermal activity (EDA).

During one of these studies, she discovered that such body signal could be accurately used for seizure detection. More research was later done at Boston Children’s Hospital, and in 2014 the Empatica Team began a series of studies at several epilepsy centers, certified as Level IV by the National Association of Epilepsy Centers (NAEC).

These studies contributed to the development of our seizure detection algorithm using Artificial Intelligence methods to recognize complex physiological patterns in EDA, that are most likely to accompany a convulsive seizure.

As more data was gathered, our data scientists have continued to work on improving the algorithm for seizure classification, and they keep working relentlessly on more clinical results in Epilepsy and human behavior.

All our efforts came to fruition on January 26, 2018, when we received word from the FDA that our application had been cleared.

This is a profound achievement for the epilepsy community at large, and it’s the first time a smart watch has been cleared within the field of Neurology.

We wouldn’t be here without our community of steadfast supporters who have kept us willing to improve throughout the years. We sincerely thank you for your trust, love and support and promise to keep working with all our heart on revolutionary technology that can improve and save lives.

Should you wish to read more on the announcement, click here

A big hug,

The Empatica Team

Words worth reading

Read more

EpiMonitor

We do not guarantee that EpiMonitor will detect every single seizure and deliver alerts accordingly. It is not meant to substitute your current seizure monitoring practices, but rather to serve as a supplement in expediting first-response time.

Company
About us
Careers
Legal
Blog
Empatica Health Monitoring Platform
Clinical Trials
Academic Research
Actigraphy
Parkinson's Monitoring
Parkinson’s & Movement Disorders
Log in
Care Portal
Care Lab Portal
Research Portal
Epilepsy Monitoring
EpiMonitor
Embrace2
Get Support
Contact Us
Manuals
Empatica
FacebookInstagramYouTubeTwitterLinkedin

Empatica Inc., 1 Broadway, 14th floor, Cambridge MA 02142 United States - Empatica Srl, Via Stendhal 36, 20144 Milano (MI), Italy

P. IVA IT07462810966. Copyright © 2026 Empatica Inc. - ISO 13485 Cert. No. 39050072201 - All rights reserved - Legal